TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Concentrations of S-flurbiprofen and R-flurbiprofen in plasma and CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Carbon Monoxide Poisoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SpHb Detection of Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SpHb in Detecting Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to relapse of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of 11C-PBB3 binding in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biodistribution of FACBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: dosimetry of FACBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Successful Imaging Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retinal vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain more than 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Pain related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of Elvitegravir in Cerebrospinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Tenofovir in Cerebrospinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine Levels in Nasal Lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene Expression in Nasal Scrapings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall clinical response rate
Endpoint domain: Mortality/survival
Primary endpoint: steady state pharmacokinetics of atovaquone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability 6 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total amount of administered fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Anxiety Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left ventricular hypertrophy in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GMT of anti-EV71 antibodies in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute Skin Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Positive and Negative Syndrome Scale Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSA and/or VRE skin colonization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adverse events (spontaneous and solicited)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in triplicate ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reversal of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate of VEGFR inhibitor-associated hand-foot skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete response rate of VEGFR inhibitor-associated hand-foot skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative Analgesia Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry Eye Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time in target range of glycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total intraoperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time to rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean viral load reduction (log10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal viral load suppression (LDL <50 & 400)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of TVS procedures with bare probe positive for HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of TVS procedures with covered probe positive for HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MRD negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Assessment Scale (DAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically important GI bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Five-day treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cardiovascular patients with a PHQ9 Score > 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exclusive or predominant breastfeeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Serum Copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of tumor down-staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall peak external frontal knee moment and impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in central retinal thickness assessed using SD-OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse events, namely cataract and elevated IOP
Endpoint domain: Adverse events/effects
Primary endpoint: End of life wish on resuscitation known or fulfilled
Endpoint domain: Mortality/survival
Primary endpoint: GOALS results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Onset Latency (SOL)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Efficacy of Nerivio during menstrual migraines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction of using Nerivio during menstrual migraines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients receiving anti-tobacco counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Isokinetic strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with the most likely diagnosis based on the five-point scale - PIRADS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with true diagnosis based on biopsy pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of images with acceptable quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tendon cross sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of study related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: ACR70 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fibroscan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minutes walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Minutes steps test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic liver diseases questionnaire (CLDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Plasma Concentration (Cmax) of Doxycycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation changes in emotions related brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in resting state functional connectivity within brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diabetes Treatment Satisfaction Questionnaire: Status (DTSQs) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diabetes Treatment Satisfaction Questionnaire: Change (DTSQc) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum observed concentration (Cmax) of tucatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent total clearance (CL/F) of tucatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epicardial potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: activation and repolarization maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Modified Gingival Index at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Bleeding Index at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to attain maximum observed plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC (0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of women terminating the diagnostic process
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Headache Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unacceptable Acute CNS Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of Human Epididymis Protein 4 (HE4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of glycoprotein CA-125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VBME resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Caries Incident Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrity of screw head
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational Balance-Questionnaire (OB-Quest)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accumulation of AGEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Bystander Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Bystander Behavior Intentions Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Bystander Behavior Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: test-retest variability of DLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: test-retest variability of MMDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to lesion regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ipsilateral ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Any Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Spinal motoneuron excitability (F wave)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal motoneuron excitability (H reflex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients Achieving Clear or Almost Clear on Physician Global Assessment (PGA) of Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Annualized Growth Velocity (AGV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean inspiratory electrical activity of the diaphragm (Edi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Youth Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Avascular necrosis post humeral head fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hepatitis B sAg status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PVT prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHANGE in Digit Span test of the Wechsler Adult Intelligence Scale - Fourth Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CHANGE in Digit Symbol and Symbol Search tests, which comprise the Processing Speed Index of the WAIS-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CHANGE in California Verbal Learning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of elderly patients with colorectal neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of handovers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sick leave days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in time to fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Acceptability/feasibility of the mHealth approach
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Forced Expiratory Volume in one second (FEV1) percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The Juniper Asthma Control Questionnaire (ACQ-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CompEx events
Endpoint domain: Adverse events/effects
Primary endpoint: Access to child mental health and substance abuse care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Engagement in child mental health and substance abuse treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Maximum relative VO2 uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Outcomes at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety profile of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Skin Cancers within the Treatment Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AK Lesions Counts/Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Clinical Response at Week 6 Based on Partial Mayo Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events of Special Interests (AESIs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Pregnancy During the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Gut Microbiome Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Morphine Equivalence Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in hallux valgus angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in Manchester-Oxford Foot Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: complication
Endpoint domain: Adverse events/effects
Primary endpoint: Effective inhibition rate of serum estradiol (E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self designed Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum observed TMC207 concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the TMC207 concentration-time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the TMC207 concentration curve from time zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injury incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Framingham 10-year Risk of Total Coronary Heart Disease (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported reasons for multiple prescribers or pharmacies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responses suggestive of misuse and/or abuse
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate Management of the Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with TSH normalization/increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Latency period interval between tocolysis and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of multidrug-resistant organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of extensively drug-resistant microorganisms
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of pan drug-resistant microorganisms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Biliary Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stress-related hormone production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Frequency of Vaso-occlusive Pain Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: persistence, relapse or superinfection of the airways at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Innate Immune Signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes